天士力(600535.SH):擬斥3.9億元參設生物醫藥股權投資合夥企業
格隆匯2月10日丨天士力(600535.SH)公佈,公司擬與深圳崇石私募股權投資基金管理有限公司(稱“深圳崇石”)、紹興濱海新區生物醫藥產業股權投資基金合夥企業(有限合夥)(稱“紹興濱海新區基金”)簽署《紹興天士力生物醫藥股權投資合夥企業(有限合夥)(籌)合夥協議》,公司以自有資金3.9億元人民幣認購紹興天士力生物醫藥股權投資合夥企業(有限合夥)(稱“紹興天士力合夥企業”、“該合夥企業”)39%份額。
該合夥企業的認繳額為10億元,合夥企業將以醫藥醫療相關產業,包括生物製藥、高端醫療器械、醫療健康大數據、精準醫療、特殊醫學用途食品等的高科技、高成長且具有良好發展前景和退出渠道的企業為主要投資方向。
深圳崇石為公司實際控制人控制的公司,根據《股票上市規則》的規定,深圳崇石為公司的關聯方,本次交易構成關聯交易。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.